---
title: "Telomir Pharmaceuticals 的股票在突破性肿瘤抑制基因重新激活数据公布后大幅上涨"
description: "Telomir Pharmaceuticals Inc.（纳斯达克股票代码：TELO）在盘前交易中股价上涨了 27.5%，原因是其实验性疗法 Telomir-1 的新数据公布。该疗法成功重新激活了前列腺癌模型中的关键肿瘤抑制基因，特别是针对 MASPIN 和另一个关键基因，表明在癌症治疗方面取得了重大突破"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260174070.md"
published_at: "2025-10-07T14:08:10.000Z"
---

# Telomir Pharmaceuticals 的股票在突破性肿瘤抑制基因重新激活数据公布后大幅上涨

> Telomir Pharmaceuticals Inc.（纳斯达克股票代码：TELO）在盘前交易中股价上涨了 27.5%，原因是其实验性疗法 Telomir-1 的新数据公布。该疗法成功重新激活了前列腺癌模型中的关键肿瘤抑制基因，特别是针对 MASPIN 和另一个关键基因，表明在癌症治疗方面取得了重大突破

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) shares surged 27.5% in premarket trading on Tuesday after the preclinical-stage biotechnology firm announced new data showing that its experimental therapy Telomir-1 successfully reactivated key tumor suppressor genes in prostate cancer models. According to the company, Telomir-1 reactivated two critical tumor suppressor genes — MASPIN (referred to as a “tumor suppressor \[…\]

### Related Stocks

- [TELO.US - Telomir Pharmaceuticals](https://longbridge.com/zh-CN/quote/TELO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| EPS Creative Health Technology to acquire 16.23% of China Genetic | EPS Creative Health Technology to acquire 16.23% of China Genetic | [Link](https://longbridge.com/zh-CN/news/275820168.md) |
| Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment | Genprex Inc. announced that IP Australia has accepted its patent application for Reqorsa® Gene Therapy combined with PD- | [Link](https://longbridge.com/zh-CN/news/275462603.md) |
| 18:01 ETBreakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression | A new study published in the International Journal of Molecular Sciences confirms HYD LLC's 30-year research on deuteriu | [Link](https://longbridge.com/zh-CN/news/275953157.md) |
| Genflow Biosciences Reports Positive Interim Results for SIRT6 Gene Therapy in Aged Dogs | Genflow Biosciences plc has reported positive interim results from its SLAB clinical trial of SIRT6 gene therapy in aged | [Link](https://longbridge.com/zh-CN/news/275712514.md) |
| Genes Tech Says Resolution To Approve Scheme Approved By Scheme Shareholders | Genes Tech Group Holdings Co Ltd :RESOLUTION TO APPROVE SCHEME WAS APPROVED BY SCHEME SHAREHOLDERSREFERS TO PROPOSAL TO  | [Link](https://longbridge.com/zh-CN/news/275917336.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。